Umm..perhaps NOT the "Best Possible Scenario". In my mind, if the success of Memantine has become a foregone conclusion, and the only hurdle the company repeatedly faces is $, $$, more $$$ then maybe its time to simply resolve this matter once and for all and strike a deal with some marketing firm. This drop at a time financing DOES dilute our stake in the company.
We are talking about 2.2 million additional shares + about 800,000 in options to buy the shares at $1. Thats approx 3 million additional shares of NTII some company would have to buy (if we are talking about a buyout) Thats about 30 percent dilution for only 1.1 million in the company coffers (+2 million if options were exercised). Thats some good deaL~!
I think NTI is selling the company out in bits and pieces, first the patents and now the shares, their vulnerable poisiton had them striking that deal with Merz, which might now make NTI uninteresting to any big Pharma, only medium sized companies wanting an additional drug in their portfolio might now be interested in NTI because of the complexity in the deal with Merz, and now we are making the price tag richer by diluting the shares and gaining almost nothing,, just think about this , what does the company get for 1.1 million, 5 months of operation, and what does NTI accomplish in 5 months, NOTHING, ABSOLUTELY NOTHING (I've seen it for months now) , at this rate what You and Me will get tomorrow will be nothing more a premuim that we would have got today or much yet before selling those rights away to Merz. They are simply wasting my time! |
